Sanofi’s atopic dermatitis drug amlitelimab hits primary endpoint, on its way to PhIII trial – Endpoints News

by

  1. Sanofi’s atopic dermatitis drug amlitelimab hits primary endpoint, on its way to PhIII trial Endpoints News
  2. Press Release: Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis Yahoo Finance
  3. Sanofi reaps rewards of immunology investment with eczema results MarketWatch
  4. ASLAN Pharmaceuticals Presents New Data From Phase 2b Study of Eblasakimab in Atopic Dermatitis in Late Breaker Presentation at 32nd European Academy of Dermatology and Venereology Congress GlobeNewswire
  5. Amlitelimab A Revolutionary Solution for Atopic Dermatitis Best Stocks
  6. View Full Coverage on Google News

Read original article here

Leave a Comment